Drugs Made In America Acquisition II Units
DMIIU10.020USD
0.000
Close 12/08, 16:00（ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Company
Drugs Made In America Acquisition II Units Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of Drugs Made In America Acquisition II Units
Name
Name/Position
Position
Shareholding
Change
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: 6 hours ago
Updated: 6 hours ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
76
45.95M
70.08%
+45.95M
2025Q3
76
45.95M
70.07%
+45.95M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
Related ETFs
Updated: 6 hours ago
Updated: 6 hours ago
Name
Proportion
SPAC and New Issue ETF
0%
SPAC and New Issue ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Drugs Made In America Acquisition II Units?
The top five shareholders of Drugs Made In America Acquisition II Units are:
What are the top three shareholder types of Drugs Made In America Acquisition II Units?
The top three shareholder types of Drugs Made In America Acquisition II Units are:
Other
Other
How many institutions hold shares of Drugs Made In America Acquisition II Units (DMIIU)?
As of 2025Q4, 76 institutions hold shares of Drugs Made In America Acquisition II Units, with a combined market value of approximately 45.95M, accounting for 70.08% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.01%.
What is the biggest source of revenue for Drugs Made In America Acquisition II Units?
In --, the -- business generated the highest revenue for Drugs Made In America Acquisition II Units, amounting to -- and accounting for --% of total revenue.
